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Context: Patients with resistance to thyroid hormone (TH) a (RTHa) are characterized by growth
retardation, macrocephaly, constipation, and abnormal thyroid function tests. In addition, almost
all RTHa patients have mild anemia, the pathogenesis of which is unknown. Animal studies suggest
an important role for TH and TH receptor (TR)a in erythropoiesis.
Objective: To investigate whether a defect in TRa affects the maturation of red blood cells in
RTHa patients.
Design, Setting, and Patients: Cultures of primary human erythroid progenitor cells (HEPs), from
peripheral blood of RTHapatients (n = 11) harboring different inactivatingmutations in TRa (P398R,
F397fs406X, C392X, R384H, A382fs388X, A263V, A263S), were compared with healthy controls
(n = 11). During differentiation, erythroid cells become smaller, accumulate hemoglobin, and ex-
press different cell surfacemarkers.We assessed cell number and cell size, and used cell staining and
fluorescence-activated cell sorter analysis to monitor maturation at different time points.
Results: After ;14 days of ex vivo expansion, both control and patient-derived progenitors
differentiated spontaneously. However, RTHa-derived cells differentiated more slowly. During
spontaneous differentiation, RTHa-derived HEPs were larger, more positive for c-Kit (a proliferation
marker), and less positive for glycophorin A (a differentiation marker). The degree of abnormal
spontaneous maturation of RTHa-derived progenitors did not correlate with severity of underlying
TRa defect. Both control and RTHa-derived progenitors responded similarly when differentiation was
induced. T3 exposure accelerated differentiation of both control- and RTHa patient–derived HEPs.
Conclusions: Inactivating mutations in human TRa affect the balance between proliferation and
differentiation of progenitor cells during erythropoiesis, which may contribute to the mild anemia
seen in most RTHa patients. (J Clin Endocrinol Metab 102: 3517–3525, 2017)
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Erythropoiesis is the process that involves the matu-ration of hematopoietic progenitor cells to differen-
tiated red blood cells (erythrocytes). Erythrocytes are of
fundamental importance for all vertebrates because they
provide cells with oxygen in exchange for carbon dioxide
(1, 2). The site of erythropoiesis changes throughout
human development. During early embryonic develop-
ment, erythropoiesis occurs in the yolk sac. By the third to
fourth month of gestation, this primitive function is taken
over by the liver. From the seventh month of gestation
onward and throughout adulthood, the bone marrow is
the predominant erythropoietic organ (3–6).
The production of sufficient numbers of mature red
blood cells requires a fine balance between proliferation
and differentiation of progenitor cells. The cytokine
erythropoietin (Epo) plays a key role in this process,
along with other growth factors, such as interleukin 3,
stem cell factor (SCF), and insulinlike growth factor I
(2, 7, 8). In addition, thyroid hormone (TH) is also im-
portant for erythropoiesis. Patients with hypothyroidism
frequently have anemia (9), and mice with congenital
primary hypothyroidism are also anemic (10). The action
of TH is mediated via binding of the active ligand (T3) to
nuclear TH receptors (TRs), TRa and TRb. TRs are
ligand-inducible transcription factors that regulate target
gene expression by binding to TH response elements in
promoters of T3-responsive genes (11–13).
Interestingly, the presence of v-ErbA, an oncogenic
homolog of TRa, disturbs the balance between proliferation
and differentiation of immature avian erythrocytes dur-
ing erythropoiesis, contributing to fatal erythroleukemia
(14–16). Additional evidence for the involvement of
T3 andTRa in erythropoiesis is provided by observations
in mice lacking TRa (TRa2/2), showing compromised
fetal and adult erythropoiesis with fewer erythroid pro-
genitors in TRa2/2 fetal livers and impaired transit of
TRa2/2 erythroblasts through further stages of matu-
ration (17). Other studies with TRa knockout mice,
displaying defective spleen erythropoiesis, confirm that
T3 via TRa stimulates late steps of erythroid develop-
ment (18).
In 2012, the first patients with resistance to THa
(RTHa) due to inactivating mutations in THRA were
discovered. All patients identified since then have
monoallelic mutations in the ligand-binding domain
of TRa. The phenotype of RTHa patients is charac-
terized by growth restriction, varying degrees of neuro-
developmental retardation, macrocephaly, constipation,
and abnormal thyroid function tests (low/low-normal FT4
and high/high-normal T3 levels with a normal thyrotropin)
(19–28). In addition, a mild, usually normochromic and
normocytic anemia is a virtually universal finding in RTHa
patients. However, in three cases the mean corpuscular
volume was raised (20, 22, 27).
Given the observations that most RTHa patients
have anemia and that aberrant TRa signaling affects
erythropoiesis in animal models, we hypothesized that
mutations in TRa affect the balance between pro-
liferation and differentiation in the later stages of
human erythropoiesis.
Patients, Materials, and Methods
Cells and cell culture
Peripheral blood (5 to 10 mL) was obtained by venesection
and collected into heparin or EDTA tubes from 11 RTHa
patients, who have been described previously (21–23, 25, 28),
and 11 healthy donors (n = 3 related and n = 8 nonrelated). The
study was approved by the Medical Ethics Committee of the
Erasmus Medical Center. Written informed consent was ob-
tained from all subjects and/or their parents. Mononuclear cells
were purified from peripheral blood by density gradient cen-
trifugation using Ficoll (Axis-Schield, Oslo, Norway).
Human erythroid progenitor cells (HEPs) were expanded
in StemSpanTM Serum-Free Expansion Medium (Stem Cell
Technologies, Grenoble, France) supplemented with lipids
(40 mg/mL cholesterol-rich lipid mix; Sigma-Aldrich, St.
Louis, MO), penicillin-streptomycin (1:100; Lonza, Basel,
Switzerland), recombinant human Epo (2 U/mL; Janssen-Cilag,
Baar, Switzerland), recombinant human SCF (100 ng/mL;R&D
Systems, Minneapolis, MN), human interleukin 3 (1 ng/mL;
R&D Systems), human insulinlike growth factor I (40 ng/mL;
R&D Systems), and dexamethasone (Dex; 1 mM; Sigma-
Aldrich) (29, 30). After 4 to 5 days, HEPs were purified by
density purification (Percoll; GE Health Care, Little Chalfont,
UK) and further expanded in StemSpan containing Epo, SCF,
and Dex.
After sufficient expansion (10 to 15 days), 10 nMT3 (Sigma-
Aldrich) was added to part of the HEPs, cultured under pro-
liferation conditions. To induce differentiation, HEPs were
washed three times with phosphate-buffered saline (Lonza) and
switched to StemSpan medium containing Epo (10 U/mL),
human serum (3%; Sigma-Aldrich), and iron-saturated trans-
ferrin (1:100; Scipac, Kent, UK).
HEPs were maintained at 1 to 1.5 3 106 cells/mL during
proliferation and at 1.5 to 2 3 106 cells/mL during differenti-
ation by daily partial medium changes. To confirm that these
cells are a good TRa-expressing model, RNA was extracted
using TRI Reagent (Sigma-Aldrich), and deep sequencing was
performed [using the Illumina Hiseq2500 platform (single read
43 bp)] in a subset of control HEPs during late proliferation
(Supplemental Fig. 1).
Cell count and morphology
The number of HEPs was daily monitored by cell count
(CASY® INNOVATIS TTC Cell Counter; Omni Life Science,
Raynham, MA). To analyze cell morphology at various stages
of proliferation and differentiation, 105 HEPs were centrifuged
onto glass slides and stained with Benzidine (Sigma-Aldrich)
to detect hemoglobin-expressing cells, and with Diff-Quick
staining (Medion Diagnostics, Miami, FL). Images were made
using an Olympus BX40 microscope (340 objective, NA 0.65;
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Olympus, America, Valley, PA) equipped with an Olympus
DP50 charge-coupled device camera (Olympus, America) and
Viewfinder lite 1.0 acquisition software (Better Light, San Carlos,
CA). The images were processed using Adobe Photoshop SC6
(Adobe, San Jose, CA).
Flow cytometry
HEPs (3 3 105 cells) were briefly centrifuged, after which
the pellet was resuspended in phosphate-buffered saline
supplemented with 0.1% bovine serum albumin and 1 mM
EDTA [fluorescence-activated cell sorter (FACS) buffer] and
stained for 30 minutes at room temperature with fluo-
rescently labeled antibodies against the following cell surface
markers (all BD Pharmingen antibodies, San Diego, CA):
CD117 (stem cell factor receptor c-Kit, dilution 1:100),
CD71 (transferrin receptor, dilution 1:100), and CD235a
[glycophorin A (GPA), dilution 1:1000] in a final volume of
100 ml. To exclude nonviable cells, 7-aminoactinomycin D
(A1310; Thermo Fisher Scientific, Waltham, MA; dilution
1:1200) was added to all samples. Fluorescence was measured
on a FACS Fortessa instrument (BD Biosciences, Oxford, UK),
and data were analyzed using FlowJo v.10.1 software (FlowJo,
Ashland, OR).
Results
Genotypic and phenotypic characterization of
RTHa patients
All 11 patients were heterozygous for amutation in the
C-terminal, ligand-binding domain of TRa1. In patients
5 to 9 (P5 to P9), the mutation (A263S/V) also affected
TRa2. When studied in vitro, the mutant receptors
showed defective hormone-dependent activation and in-
hibited wild-type TRa1 function in a dominant-negative
mannerwhen coexpressed (22, 24). The severity of mutant
receptor dysfunction varied depending on the type of
the mutation. Patients 1 to 3 (P1 to P3) have frameshift/
premature stop, and P4 a nonsense mutation, all gener-
ating a truncated receptor with negligible T3-induced
transcriptional activity and marked dominant-negative
activity. In contrast, P5 to P11 have missense mutations
that cause reduced T3 sensitivity.
All RTHa patients with a severe mutation (P1 to P4),
as well as most patients with milder mutations (P5 to P7
and P9 to P11), exhibited mild anemia. There was no
correlation between the severity of the mutations and
hemoglobin levels or red blood cell count (Table 1).
Except for P4, P9, and P11, RTHa patients were treated
with levothyroxine (LT4).
Delayed spontaneous differentiation in HEPs of
RTHa patients
Peripheral bloodmononuclear cells were isolated from
RTHa patients and healthy controls and cultured in
conditions permissive for proliferation. The population
of expanding HEPs was purified by Percoll density
centrifugation after 4 to 5 days, depending on the number
of cycling progenitor cells at day 0. Once homogenous
HEP populations were established (after 10 to 15 days),
cultures were monitored daily for cell number and
cell size.
After;2 weeks of proliferation, normal HEPs start to
differentiate spontaneously, a process characterized by a
decrease in proliferation rate, reduced cell size, cyto-
plasmic acidification, hemoglobin production, and nu-
clear condensation, followed by enucleation (31). This
reduction in growth rate and cell size was delayed in the
RTHa cells, suggesting reduced spontaneous differen-
tiation capacity in these cells. This was further studied
by Benzidine/Diff-Quick staining of cytospin prepara-
tions. Proliferating, hemoglobin-negativeHEPs appear as
large cells with blue cytoplasm, whereas differentiating,
hemoglobin-positive HEPs are smaller with brown cy-
toplasm (18) (Fig. 1) (29). Consistent with our hypoth-
esis, at a late phase of proliferation (culture day ;14),
cytospin preparations from control cultures (n = 11)
showed a substantial number of cells with differentiated
morphology, marked by smaller and dark-stained cells.
In contrast, preparations from RTHa patients (n = 11)
showed predominantly large light-stained cells, indi-
cating that most cells had not yet entered the differen-
tiation program [Fig. 2(a)].
The difference in cell size was confirmed by flow
cytometry analysis. To distinguish large cells from small
cells, a cutoff of $100 K was used, measured with
forward scatter. The forward scatter showed that cells
from RTHa patients (n = 11) had a larger mean size
compared with cells of controls (n = 11; 41.7%of cells in
patients vs 23.6% in controls had a forward scatter
index larger than 100 K, P = 0.001), indicating that
many RTHa HEPs were still expanding, whereas the
majority of control HEPs had started their differentia-
tion program [Fig. 2(b)].
HEPs express stage-specific cell surface proteins dur-
ing different phases of erythropoiesis. CD-117 (c-Kit) is a
marker of immature erythroblasts, andCD71 (transferrin
receptor) expression increases during early differentia-
tion, whereas GPA (CD235a) is a marker for mature
erythroid cells (29, 32). During the later stages of pro-
liferation (culture day ;14), control HEPs (n = 11) were
predominantly negative for c-Kit, as illustrated by an
accumulation of HEPs in the c-Kitnegative subgate [Fig.
2(c)]. However, RTHaHEPs (n = 11) accumulated less in
the c-Kitnegative subgate (37.2% in patients vs 74.5%
in controls, P , 0.0001), corresponding to a delayed
maturation stage. In addition, RTHa patients (n = 9, due
to insufficient cells in two samples for GPA staining)
showed less HEPs in the GPAhigh subgate compared with
controls (n = 9; 29.6% in patients vs 59.7% in controls,
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P = 0.003), again indicating that RTHa HEPs display a
reduced or delayed spontaneous differentiation rate com-
pared with control HEPs [Fig. 2(d)].
Despite similar culture conditions, the period in which
cells could be maintained in culture varied slightly be-
tween different experiments. Nevertheless, for all ex-
periments, the longer the cells were cultured, the more
cells differentiated fully and then became apoptotic, re-
ducing availability of cell samples for experiments fo-
cusing on later stages of maturation. No differences in the
extent of apoptosis between patient and control HEPs
were observed. Patient cells (n = 7) and control samples
(n = 5)were furthermonitored during culture days;15 to
20, still under proliferative conditions. The first signs of
differentiation of RTHa cells were observed at ;day 16,
;2 days later than control cells. At this time point, the
majority of the cells was reduced in size, but did not stain
for hemoglobin [Fig. 3(a), top panel]. After ;20 days of
culture, apoptosis occurred in fully
differentiated cells from most controls
and RTHa patients, with no dif-
ferences between cells with either
frameshift/stop or missense mutations.
Longer-term observations were made
with the samples that still contained
viable cells. After ;20 days, the culture
of control cells (n = 2) was terminated,
as these cells were fully differentiated
and started to disintegrate. In contrast,
most RTHa cultures (n = 3) contained
twoviable subpopulations: differentiated,
hemoglobin-positive cells, and immature
blasts [Fig. 3(a), lower panel]. Although
the number/percentage of blasts varied per patient/mutation,
these immature cells could be maintained for an additional 5
to 7 days, followed by apoptosis. The differences in cell size
between RTHa and control cultures during the different
stages are shown in Fig. 3(b).
The delay in spontaneous differentiation of RTHa
cells was also confirmed by FACS analysis. During
differentiation, a large proportion of RTHa HEPs be-
came negative for c-Kit and simultaneously increased the
expression of GPA. Values for c-Kit and GPA expression
in RTHa-derived cells reached levels comparable to
controls, but with a delay of 4 days (Supplemental Fig. 2).
During this period, expression values of the different cell
surface markers in the control cells did not change, as
maximal levels were already reached.
Taken together, these results show that onset of spon-
taneous differentiation is delayed in RTHa HEPs. How-
ever, when RTHa cells finally differentiate, differences
Table 1. Hematological Data of RTHa Patients
Subject Mutation Sex Age LT4 Hb Ht RBC MCV MCH Reticulocytes Platelets WBC
P1 F397fs406X F 16 Yes 11.1 (12.5–16.0
g/dL)
0.34 (0.37–0.47
L/L)
3.95 (4.2–5.4 3
1012/L)
86.6 (78–100 fL) 28.1 (27–31 pg) 0.9 (0%–2%) 235 (150–4003
109/L)
9.07 (4.0–11.03
109/L)
P2 F397fs406X M 52 Yes 13.3 (13.5–18.0
g/dL)
0.38 (0.42–0.52
L/L)
4.20 (4.3–5.9 3
1012/L)
89.5 (78–100 fL) 31.1 (27–31 pg) 0.89 (0%–2%) 203 (150–4003
109/L)
6.47 (4.0–11.03
109/L)
P3 A382PfsX7 F 48 Yes 12.0 (11.5–16.0
g/dL)
0.36 (0.35–0.46
L/L)
3.42 (3.8–0.5.33
1012/L)
104 (80–100 fL) 35.1 (27–32 pg) 0.67 (0.32%–2.5%) 95 (150–400 3
109/L)
4.80 (4.0–11.03
109/L)
P4 C392X M 20 No 9.3 (12.0–16.5
g/dL)
28.4 (0.36–0.50
L/L)
3.12 (4.0–5.5 3
1012/L)
91.1 (80–100 fL) 29.7 (26–34 pg) 154 (150–4003
109/L)
4.6 (4.0–10.0 3
109/L)
P5 A263S M 4 Yes 11.0 (11.0–16.0
g/dL)
0.32 (0.35–0.48
L/L)
3.88 (4.0–0.6.03
1012/L)
84.4 (80–100 fL) 28.2 (28–32 pg) 0.47 (0.5%–1.5%) 255 (150–4003
109/L)
8.97 (4.5–10.53
109/L)
P6 A263S F 7 Yes 10.8 (11.0–16.0
g/dL)
0.32 (0.35–0.48
L/L)
3.91 (4.0–0.6.03
1012/L)
83.6 (80–100 fL) 27.6 (28–32 pg) 0.51 (0.5%–1.5%) 268 (150–4003
109/L)
4.38 (4.5–10.53
109/L)
P7 A263S F 31 Yes 9.6 (11.0–16.0
g/dL)
0.31 (0.35–0.48
L/L)
3.80 (4.0–0.6.03
1012/L)
82.0 (80–100 fL) 25.2 (28–32 pg) 0.43 (0.5%–1.5%) 206 (150–4003
109/L)
4.02 (4.5–10.53
109/L)
P8 A263S M 55 Yes 13.5 (13.5–17.5
g/dL)
0.40 (0.41–0.53
L/L)
4.34 (4.0–0.6.03
1012/L)
94.4 (80–100 fL) 31.2 (28–32 pg) 1.49 (0.5%–1.5%) 249 (150–4003
109/L)
5.18 (4.5–10.53
109/L)
P9 A263V M 17 No 11.9 (13.0–17.0
g/dL)
0.36 (0.37–0.49
L/L)
3.79 (4.5–0.5.33
1012/L)
94.4 (78–100 fL) 31.5 (28–32 pg) 58.9 (20–1203 109/L) 170 (150–4003
109/L)
5.9 (4.0–11.0 3
109/L)
P10 R384H F 35 Yes 10.7 (11.0–16.0
g/dL)
0.34 (0.35–0.48
L/L)
3.91 (4.0–6.0 3
1012/L)
86.1 (78–100 fL) 27.2 (28–32 pg) 1.60 (0.5%–1.5%) 241 (150–4003
109/L)
4.90 (4.5–10.53
109/L)
P11 P398R F 8 No
Because blood samples were obtained from anonymous healthy blood donors (3 females, 8 males, age range 18 to 61 years), exact hematological data
were not available. However, none of the donors had anemia because, for donation, one’s hemoglobin level is required to be within the reference range
(12.5 to 17.5 g/dL for female donors, and 13.5 to 19.0 g/dL for male donors of Sanquin Blood Bank).
Abbreviations: Hb, hemoglobin; Ht, hematocrit; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; RBC, red blood cell; WBC, white
blood cell.
Figure 1. Flow chart of methods. IGF1, insulinlike growth factor 1.
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between RTHa and control cells diminish, albeit with
RTHa HEPs lagging behind control HEPs.
Induced differentiation proceeds similarly in RTHa
and control HEPs
Optimal and synchronous differentiation of HEP cells
can be induced by changing the culture conditions. To
study optimal or forced differentiation, HEPs were
switched to StemSpan medium containing a high con-
centration of Epo (10 U/mL), human serum, and trans-
ferrin, whereas the proliferation factors (SCF and Dex)
were removed. After 6 days of induced differentiation,
cell populations of the remaining RTHa patients (n = 3)
and controls (n = 2) predominantly consisted of small,
dark-stained, and enucleated cells [Fig. 3(c)]. The ex-
pression of the different cell surfacemarkers did not differ
significantly between RTHa HEPs and control HEPs
(Supplemental Fig. 2).
In summary, under forced differentiation conditions,
RTHa cells differentiate nearly as well as control cells.
T3 enhances spontaneous differentiation of
RTHa HEPs
It has been shown that addition of T3 does improve the
differentiation characteristics of erythroid progenitors
when grown ex vivo (16). To investigate the effect of T3
on RTHa HEPs, we exposed part of the RTHa (n = 7)
and control HEP cultures (n = 5), at later stages of
Figure 2. Spontaneous differentiation is delayed in HEPs from RTHa patients. (a) Benzidine- and Diff-Quick–stained cytospins of RTHa-derived
(P4; C392) and control HEPs. After 2 weeks of proliferation (day 14), control HEPs start to differentiate spontaneously, illustrated by smaller and
dark-stained (hemoglobin-containing) cells. In contrast, cytospin preparations from RTHa-derived HEPs show predominantly large, weakly stained
cells that are still proliferating. (b) FACS analysis of RTHa-derived and control HEPs after 2 weeks of proliferation (day 14). RTHa-derived HEPs
had a larger mean size compared with control HEPs, illustrated by the percentage of cells with a forward scatter index large than 100 K (41.7%
of cells in patients vs 23.6% in controls, P , 0.001). (c) FACS analysis of RTHa-derived and control HEPs during late proliferation (culture day
;14). RTHa-derived HEPs express predominantly c-Kit, a proliferation cell surface marker (37.2% of cells in patients vs 74.5% of cells in controls
accumulate in the c-Kitnegative subgate, P , 0.0001). (d) In contrast, the majority of control HEPs express differentiation cell surface markers
(CD71 and GPA) (29.6% of cells in patients vs 59.7% of cells in controls accumulate in the GPAhigh subgate, P , 0.01).
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proliferation (;day 14), to 10 nM T3. After 2 days, this
resulted in an increased proportion of differentiated
HEPs when compared with HEPs cultured without T3,
with a similar effect in RTHa and control samples. Cells
in treated samples were smaller (Fig. 4), stained less for c-
Kit, and were more positive for GPA (Supplemental
Fig. 3).
Discussion
In the current study, we show that inactivating mutations
in TRa affect the balance between proliferation and
differentiation in HEPs. Ex vivo studies show that RTHa
HEPs have a reduced capacity to differentiate sponta-
neously in comparison with control HEPs.
Several studies in humans have documented an asso-
ciation between hypothyroidism and reduced red blood
cell counts, identifying mild anemia in 20% to 60% of
hypothyroid patients (9, 33). Studies in avian and murine
models point toward involvement of TRa in later stages
of erythropoiesis (17, 18, 34–37). However, it is im-
portant to point out that there are significant differences
in the physiology of normal erythropoiesis between
murine and human contexts. For example, inmice, stress-
induced erythropoiesis occurs in spleen, which is not the
case in humans (18).
Because (mild) anemia, mostly normocytic normo-
chromic, is also a common characteristic in RTHa pa-
tients (20–26, 28), we decided to investigate whether a
defect in TRa affects the red cell maturation in RTHa
patients. In this context, we sought to study whether
tissue-specific hypothyroidism due to mutations in TRs
affects erythropoiesis to a similar extent as primary hy-
pothyroidism. The use of a well-validated cell culture
Figure 3. Differences between differentiating RTHa-derived and control HEPs decrease wherein RTHa-derived HEPs remain just behind control
HEPs. (a) Cytospin preparations of RTHa-derived (P5; A263S) and control HEPs at day 16 (early spontaneous differentiation) and day 20 (late
spontaneous differentiation). (b) Differences in cell size between RTHa-derived and control cultures during the different stages of differentiation,
measured by flow cytometry analysis using forward scatter. To distinguish large cells from small cells, a cutoff of $100 K was used. (c) Cytospin
preparations of RTHa-derived (P1; F397fs406X) and control HEPs after 6 days of induced differentiation, in which HEPs were cultured in StemSpan
medium containing a high concentration of Epo, human serum, and transferrin.
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protocol (29, 30) allowed us to expand the limited
number of hematopoietic progenitors present in pe-
ripheral blood samples of both RTHa patients and
healthy controls.
We were able to synchronize the development of HEPs
at the proerythroblast stage, when cells show the first
morphologically recognizable features of erythroid cells.
From this stage, we studied the maturation of the HEPs
using serum-free medium containing proliferation fac-
tors. Remarkably, RTHa HEPs continued to proliferate
for a prolonged period, whereas control HEPs started to
differentiate spontaneously from day 14. This delay in
maturation and development was evident from both
morphological appearance and expression of cell surface
markers at this stage (2, 29). The serum-free culture
medium used in our experiments contained low levels of
T3 (;0.5 nM), which may have been sufficient to en-
hance differentiation in control HEPs by activation of
wild-type TRa. However, in RTHa-derived HEPs, such
low T3 concentrations were probably unable to induce
differentiation to a similar extent as these cells harbored
mutant TRa with reduced T3 affinity, resulting in a
prolonged proliferation phase (13).
For efficient terminal maturation, proliferation factors
in the medium need to be replaced by differentiation
factors (higher concentration of Epo, transferrin, serum).
Addition of serum is necessary for complete down-
regulation of c-Kit and a further induction of GPA in
human erythroblasts, both characteristics of terminal
differentiation (30). Under such optimal differentiation
conditions, differences between RTHa-derived and con-
trol HEPs decreased. This suggests that TRa mutations
most likely affect the timing of onset of differentiation
and influence the actual differentiation process itself to a
lesser extent.
To investigate whether higher concentrations of T3
could overcome such delayed maturation dynamics,
cultured HEPs during late proliferation were exposed to
10 nMT3. After 2 days,HEPs of bothRTHa-derived and
control T3-treated cells showed a modest decrease in cell
size, indicating an increased proportion of spontaneous
differentiation. This observation is consistent with pre-
vious findings from Leberbauer et al. (30), showing that
proliferating HEPs treated with T3 have a gradual de-
crease in cell size, reduced proliferation rates, and higher
hemoglobin content.
Previous studies indicate that exposure of normal
HEPs to T3 does not affect expression of differentiation
cell surface markers (30), and we confirmed these find-
ings with control HEPs in this study. In contrast, RTHa
HEPs exposed to 10 nM T3 showed a slight increase
in CD71 and GPA expression together with down-
regulation of c-Kit levels. One explanation for these
findings is that levels of T3 present in normal medium are
sufficient to permit differentiation of control HEPs with
higher exogenous T3 concentrations following addition
of exogenous hormone only shifting the balance of cells
achieving terminal maturation. In contrast, in RTHa-
derived HEPs, harboring dysfunctional TRa, higher T3
concentrations could help overcome the TRa defect,
thereby accelerating the onset of spontaneous differen-
tiation. Previous characterization (20–28) of TRa mu-
tations identified in RTHa cases indicates variable
dysfunction with frame shift and nonsense mutations
being markedly more deleterious than missense muta-
tions (with some proximal receptor mutations also af-
fecting TRa2). In this context, both in the current study
and in reports of other published RTHa cases, there is no
association between the degree of anemia and the severity
of mutations in TRa. Furthermore, there is no re-
lationship between hemoglobin concentrations or red
blood cell number and TH levels in cases, all showing
inherent variation among different subjects. Given these
in vivo findings in RTHa, it is not surprising that the
Figure 4. Cytospin preparations of RTHa-derived (P4; C392X, P5; A263S) and control HEPs at day 16 cultured with and without 10 nM T3 for
2 days. Addition of T3 resulted in an increased proportion of morphologically differentiated HEPs in both RTHa patients and controls. The decrease in
cell size was significant in control HEPs.
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maturation dynamics of RTHa HEPs, harboring TRa
mutations of varying severity, did not differ. Despite the
anemia, the number of reticulocytes was not increased in
RTHa patients, suggesting that the release of immature
erythrocytes into the circulation is not altered. In addi-
tion, no major abnormalities in other blood cell lineages
were detected. However, we were not able to measure the
life span of erythrocytes in our patients in vivo; ac-
cordingly, we cannot discount the possibility that the life
span of RTHa erythrocytes is altered compared with
healthy controls.
Cultured, RTHa-derived HEPs responded to 10 nM
T3 exposure, whereas LT4 treatment did not correct
anemia in most patients with RTHa. One possible ex-
planation for this discrepancy is that mutant TRa affects
earlier phases of erythrocyte development in the bone
marrow in RTHa patients, which we have not been able
to examine in this study. In the current project, we studied
relatively late stages of erythrocyte maturation, in which
T3 is known to favor differentiation of erythrocytes (38).
In this phase, addition of higher T3 concentrations
stimulated the onset of differentiation in both RTHa-
derived and control HEPs. However, it remains unclear
whether T3 via TRa similarly affects earlier stages of
erythrocyte development and, if so, whether LT4 treat-
ment of RTHa patients can rescue mutant TRa function
in this earlier phase.
In addition, we cannot discount the possibility that
culture of isolatedHEPs ex vivo enables different facets of
the maturation process to be studied and regulated by
exposure to T3, whereas it is more difficult to influence
the likely complex interactions between HEPs with other
cell types and factors that control the maturation process
in vivo, with TH treatment. Thus, in addition to intrinsic
differences between RTHa and normal erythrocyte
progenitors, it is conceivable that such added interactions
contribute to the anemia of RTHa patients.
In conclusion, by studying erythroid progenitor cells
from RTHa patients ex vivo, we have shown that both
TH and TRa play a role in the later phases of human
erythropoiesis. Erythrocyte progenitors from RTHa
patients exhibit defective maturation capacity, with later
onset of, and a slower progression through, the terminal
differentiation program.
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